Understanding the CGHS Reimbursement Policy Crisis

The CGHS Reimbursement Policy is currently at the center of a significant healthcare debate in India. Consequently, private hospital associations are warning that a new reimbursement cap could jeopardize access to advanced oncology treatments. The Association of Healthcare Providers (India) recently flagged this issue in a letter to the health ministry. Specifically, the current cap limits hospital payments to only 70% of the Maximum Retail Price (MRP) for high-cost drugs. This financial shortfall is forcing hospitals to absorb significant costs out-of-pocket for expensive patented medicines. As a result, the sustainability of cancer care for thousands of government employees is now under threat.

The Impact of the CGHS Reimbursement Policy on Care

This policy affects at least nine vital immunotherapy drugs, including Keytruda and Enhertu. Furthermore, hospitals argue that the current pathways for drug procurement are medically dangerous for patients. One proposed option involves patients sourcing their own medicines from external outlets. However, doctors are reluctant to administer such drugs because they cannot verify their storage conditions. Maintaining a strict cold chain is essential for preserving the efficacy of these biologics. Therefore, patients may face suboptimal outcomes if the integrity of the drugs is compromised during transport.

Operational and Legal Roadblocks

Hospitals also face legal risks due to their bulk procurement contracts with pharmaceutical companies. These contracts often prohibit the disclosure of negotiated prices to third parties like government agencies. Consequently, submitting purchase invoices could lead to breach of contract claims or supply disruptions. Additionally, the internal CGHS supply system has proven unreliable, often suffering from stock shortages. Because margins on these patented drugs are slim, hospitals cannot sustain the current 30% loss. Ultimately, a revision of the reimbursement rates is necessary to ensure continued access to life-saving therapies.

Frequently Asked Questions

Q1: Why is the 70% reimbursement cap problematic for hospitals?

Hospitals have narrow margins on high-cost patented drugs. Capping reimbursement at 70% of the MRP forces them to pay the remaining 30% out-of-pocket, making treatment financially unsustainable.

Q2: What are the risks of patients sourcing their own oncology drugs?

Biological drugs like immunotherapy require strict temperature controls. If a patient sources them independently, the hospital cannot guarantee the cold chain was maintained, risking drug degradation and patient safety.

Q3: Which drugs are primarily affected by this policy change?

The crisis involves several high-cost patented drugs, including Keytruda, Imfinzi, Enhertu, and Zoladex, which are essential for treating advanced cancers.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Hospitals warn Central Government Health Scheme reimbursement cap may hurtcancer treatment - ETHealthworld


2. Max Healthcare discontinues patented cancer drugs, writes to CGHS to review pricing - Business Today


3. India Hospitals Warn: Cancer Drug Reimbursement Cap Threatens Patient Access - Whalesbook